.jpg)
Allosteric inhibitors of Akt protein for the treatment of Leishmaniasis and Chagas disease.
✓ Patent granted in Colombia: NC2017/0000871
Neglected or neglected diseases are a group of infectious diseases, many of them parasitic that mainly affect the poorest populations with limited access to health services. Leishmaniasis and Chagas disease are part of this group. These two diseases, with high morbidity rates per year, generate high costs to the health system and families. Given these characteristics and the complex host-parasite interactions, the disease is difficult to treat given the limited number of drugs available for its treatment. In response to the aforementioned problem, the Program for the Study and Control of Tropical Diseases -PECET- of the University of Antioquia, has developed an orally administered drug that uses compounds that inhibit the Akt protein of the parasites Leishmania panamensis and Trypanosoma cruzi, to be used as a therapeutic agent for the treatment of both diseases.
*APPLICATIONS: ✓ Prophylaxis and treatment of Leishmaniasis and Chagas disease. *ADVANTAGES-BENEFITS: ✓ The treatment is specific, differentiating it from current commercial treatments, which generate side effects and can be very toxic for the patient. ✓ The compounds present low toxicity and comply with the Lipinski rule, i.e., they are compounds that, due to their chemical characteristics, can be supplied in an oral composition, generating greater adherence to treatment by patients. ✓ It is expected that the production of the compounds can be carried out at a competitive price.